Communication problems holding back new cancer treatments Cancer immunotherapy is revolutionising oncology – but the Havas Lynx Group’s chief medical officer Vernon Bainton argues that the incredible progress is Share XCommunication problems holding back new cancer treatments https://pharmaphorum.com/oncology/communication-problems-holding-back-new-cancer-treatments/
The power of blockchain in cancer care transformationOver the course of the last decade blockchain technology has slowly filtered through from the underground to the Share XThe power of blockchain in cancer care transformationhttps://pharmaphorum.com/views-and-analysis/blockchain-power-cancer-care/
Oncolytics: the dawn of a new era in cancer treatmentOncolytic virus therapy is not a new discovery, but it may now be positioned as the next major Share XOncolytics: the dawn of a new era in cancer treatmenthttps://pharmaphorum.com/views-analysis-oncology/oncolytics-new-era-cancer-treatment/
Placing patient values at the centre of cancer treatment – a doctor’s insightDr Michael Wong is professor of medicine at The University of Texas MD Anderson Cancer Center. He also Share XPlacing patient values at the centre of cancer treatment – a doctor’s insighthttps://pharmaphorum.com/views-analysis-patients/patient-values-centre-cancer-treatment/
Changing our approach to treatment decision making – an interview with Amy BermanAmy Berman is a senior programme officer with The John A. Hartford Foundation, a private philanthropy dedicated to Share XChanging our approach to treatment decision making – an interview with Amy Bermanhttps://pharmaphorum.com/views-analysis-patients/changing-approach-treatment-decision-making/
ASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint comboBreast cancer has been one area where checkpoint inhibitors have not yet gained traction – but that might Share XASCO 2018 – Tuesday 5th June: Tesaro developing checkpoint combohttps://pharmaphorum.com/views-and-analysis/asco-2018-tesaro-checkpoint-combo/
ASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and moreBristol-Myers Squibb is hoping to revive its Opdivo cancer immunotherapy by combining it with an experimental agent from Share XASCO 2018 – Sunday 3rd June: Opdivo/Nektar, AbbVie’s new leukaemia combo, and morehttps://pharmaphorum.com/views-analysis-oncology/asco_2018-opdivo-nektar-abbvies-leukaemia/
ASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerThe American Society of Clinical Oncology (ASCO) has already singled out CAR-T therapies as the most promising advance Share XASCO 2018 – Friday 1st and Saturday 2nd June: Bluebird Bio’s CAR-T shines, plus blood tests for lung cancerhttps://pharmaphorum.com/views-analysis-oncology/asco-round-up-bluebird-bios-car-t-plus-lynch-syndrome-screening/
ASCO 2018 Preview – what to expect from this year’s conferencepharmaphorum will be presenting live online coverage of this year’s ASCO 2018 conference, the biggest event of the Share XASCO 2018 Preview – what to expect from this year’s conferencehttps://pharmaphorum.com/views-and-analysis/asco-2018-preview-conference/
